Risk Assessment in Adult T-Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Makoto Yoshimitsu, Ryuji Tanosaki, Koji Kato, Takashi Ishida, Ilseung Choi, Yoshifusa Takatsuka, Takahiro Fukuda, Tetsuya Eto, Michihiro Hidaka, Naoyuki Uchida, Toshihiro Miyamoto, Yasuhiro Nakashima, Yukiyoshi Moriuchi, Koji Nagafuji, Yasuhiko Miyazaki, Tatsuo Ichinohe, Minoko Takanashi, Yoshiko Atsuta, Atae Utsunomiya, ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2017 Nov 16Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pre-transplant prognostic factor of HCT in adult T-cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-comorbidity index [CI]/modified European Society for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematological malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict non-relapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 vs. HCT-CI 1-3 and HCT-CI 0 vs. HCT-CI ≥4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0-3 with 4-6. As ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor/recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0%, 27.7%, and 44.4%, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients. Copyright © 2017. Published by Elsevier Inc.
Citation
Makoto Yoshimitsu, Ryuji Tanosaki, Koji Kato, Takashi Ishida, Ilseung Choi, Yoshifusa Takatsuka, Takahiro Fukuda, Tetsuya Eto, Michihiro Hidaka, Naoyuki Uchida, Toshihiro Miyamoto, Yasuhiro Nakashima, Yukiyoshi Moriuchi, Koji Nagafuji, Yasuhiko Miyazaki, Tatsuo Ichinohe, Minoko Takanashi, Yoshiko Atsuta, Atae Utsunomiya, ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Risk Assessment in Adult T-Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Nov 16
PMID: 29155320
View Full Text
